QSAR Models for Prediction of Binding and Inhibitory Properties of [(E)-2-R-vinyl]benzene Derivatives with Therapeutic Effects against *Helicobacter pylori*

Juan J Galano and Javier Sancho

Department of Bioquímica y Biología Molecular y Célular, Facultad de Ciencias, Universidad de Zaragoza, Pedro Cerbuna 12, 50009, Zaragoza, Spain

Biocomputation and Complex Systems Physics Institute (BIFI), Joint Unit BIFI-IQFR (CSIC), Edificio I+D, Mariano Esquillor, 50018, Zaragoza, Spain

Abstract

*Helicobacter pylori* is a gram-negative bacterium that infects the luminal surface of the human gastric epithelium. Around one half of the world’s population is thought to be infected by this bacterium, which is able to develop diseases such as peptic ulcer or gastric cancer. Eradication of *Helicobacter pylori* is becoming increasingly difficult due to resistance to common antibiotics. In previous work we have shown that an essential protein, flavodoxin, constitutes a target for the development of novel, specific antibiotics against infection caused by this microorganism, and we have described compounds sharing the [(E)-2-R-vinyl]benzene scaffold that exhibit bactericidal properties against *Helicobacter pylori* cultures. Based on the affinity and activity of 24 such compounds we have now developed QSAR models for affinity and minimal inhibitory concentration that will guide the improvement of antibacterial compounds based in the [(E)-2-R-vinyl]benzene scaffold. The two models show high statistical correlation and predictive capacity. Discovering novel chemicals with specific antimicrobial properties against *Helicobacter pylori*, and presumably not affected by existing resistances, will be of great help for the treatment of the diseases associated with this bacterium.

Keywords: *Helicobacter pylori*, Flavodoxin, Antibiotic, Antimicrobial; Inhibitor; QSAR

Introduction

The classical Quantitative Structure-Activity Relationship (QSAR) as we know them today) emerged in the first half of the 60s with the early works of Hansch and Fujita [1], the Free-Wilson method [2], the subsequent modification made by Ban [3] and the later approaches proposed by Kubinyi [4-10] and Topliss [11]. QSAR, assisted by a wealth of organic synthetic techniques, computer technologies and by the discovery of many potential therapeutic targets, has since become a central tool for chemists, biologists and biochemists in search of improving active compounds to use them as drugs for the treatment of a variety of diseases.

*Helicobacter pylori* (*Hp*) is a gram-negative bacteria that establishes life-long infections in the gastric mucosa of infected people [12,13]. Nowadays, about 50% of the global population is believed to be infected by *Hp*, with a lower prevalence in Europe and the United States but much higher in developing countries [14]. The presence of *Hp* in the human gastric mucosa is related to the development of diseases such as type B gastritis, chronic peptic ulcers and gastric neoplasias on individuals infected by that microorganism.

The traditional treatment used worldwide to combat *Hp*, known as the triple therapy (one proton pump inhibitor together with two wide spectrum antibiotics: clarithromycin and a choice of amoxicillin or metronidazole) [15], has unfortunately lost efficacy due to increased resistances. No new drugs have been developed in recent years to treat *Hp* infection, but some selective targets (one of them being the protein flavodoxin: *Hp*-Fld) have been identified [16]. *Hp*-Fld is an electron carrier essential for *Hp* viability [17,18] and it has been used in previous works [19,20] as target for the discovery of novel compounds that could be potential drugs against *Hp*. Four different biological responses (BR) or biological activities were assayed for those novel compounds, which are mainly derived from a common substructure represented in Figure 1. From those data we have gathered a database of 24 congenic compounds and their respective biological activity values. We describe here two QSAR models for the binding affinity and the therapeutic potency of bactericidal compounds based on the [(E)-2-R-vinyl]benzene scaffold (Figure 1), which will guide the future improvement of *Hp*-specific bactericides.

Materials and Methods

Data set for QSAR analysis

Four *Hp* flavodoxin inhibitors were identified in previous work [19] and subsequently optimized [20]. Three of them, originally named C1, C2 and C4, were shown to display bactericidal activity against *Hp*. Compounds C1 and C2 are structurally related as they contain the common [(E)-2-R-vinyl]benzene substructure (Figure 1). In this work, those two compounds are referred to as I and II to retain their initial numbering. Twenty two additional compounds: 7 and 15 analogues of I and II respectively, were selected from [20]. The numbering assigned to them in that work [20] is retained here for clarity (Table 1). Compounds I, II, plus the additional 22 compounds constitute the database that we have used for the development of the QSAR models.

Cluster analysis (CA) was used to assess the structural diversity of such compounds by checking that relatively balanced distributions of compounds for a given cluster number were obtained, and to design the training (80%) and test (20%) series. Agglomerative hierarchical clustering was performed starting with each point as a singleton cluster and then repeatedly merging the two closest clusters until a single all-encompassing cluster remained. The “centroid method”
was used to merge objects into clusters, and distance between two clusters was defined as the squared Euclidean distance between their respective centroids [21]. The clustering was performed using the STATGRAPHICS 5.1 program [22].

As described elsewhere [20], the biological response variables (BR) tested for each compound were: affinity (Kd) of the compound/Hp-Fld complex, minimal inhibitory concentration (MIC), minimal cytotoxic concentration (MCC), and therapeutic index (TI=MCC/MIC). Normality for each BR (i.e., the fit to a Normal statistical distribution) was checked and, in cases where it was not met, some compounds were removed to obtain a dataset with Normal distribution. For QSAR analyses each BR was expressed as LogBR.

Molecular descriptors

A large number of molecular descriptors (MD) can be used in QSAR studies [23] (e.g., the latest version of the DRAGON program [24] calculates over 4800 MDs). The specific biological action of drugs may be described by a combination of hydrophobic, electronic and steric properties. A total of 35 MDs, mostly related to those properties and easily interpretable, have been selected for the current work. We have considered as hydrophobic descriptor the logarithm of the octanol-water partition coefficient (Log P) which has been calculated through Ghose-Crippen methodology [25,26] implemented in DRAGON 6. The four electronic descriptors used: total dipole moment (µ), total energy (ET), HOMO eigenvalue and LUMO eigenvalue, were calculated

### Table 1: Observed values for tested BRs in selected compounds.

| Cp* | Structure | Kd | MIC (µM) | MCC (µM) | TI |
|-----|-----------|----|----------|----------|----|
| I   | ![Structure](image1) | 1  | 1.2      | 6        | 5.0 |
| 1c  | ![Structure](image2) | 0.43 | 2.4      | 1        | 0.4 |
| 2c  | ![Structure](image3) | 1.5 | 2.4      | 6        | 2.5 |
| 3c  | ![Structure](image4) | 1.7 | 2.4      | 6        | 2.5 |
| 4c  | ![Structure](image5) | 0.78 | 1.2      | 10       | 8.3 |
| 5c  | ![Structure](image6) | 1.9 | 7.5      | 70       | 9.3 |
| 6c  | ![Structure](image7) | 25 | 2        | 10       | 5.0 |
| 7c  | ![Structure](image8) | 1.8 | >150     | 12       | <0.08 |
| 31c | ![Structure](image9) | 3.5 | 2.4      | 3.5      | 1.5 |
| 32c | ![Structure](image10) | 7.9 | 4.75     | 40       | 8.4 |
| 33c | ![Structure](image11) | 5.5 | 2.4      | 0.70     | 0.3 |
| 34c | ![Structure](image12) | 10  | 8        | 0.01     | 0.001 |
| 35c | ![Structure](image13) | 8.8 | 2.4      | 0.1      | 0.04 |
| 36c | ![Structure](image14) | 0.67 | 2.4      | 2        | 0.8 |

*The same number of compound given in [20]
1Values calculated as MCC/MIC
4Derivatives of inhibitor I and II respectively
by quantum mechanical procedures using the MOPAC 6 software [27] with the Austin Model 1 (AM1) semi-empirical Hamiltonian [28] after full geometrical optimization of each molecule. Three additional descriptors were calculated based on the previous ones: electrophilicity index ($\omega$) [29], chemical hardness ($\eta$) and softness ($\iota$) [30]. The polarizability property ($\text{Pol}$) [31] was calculated from the partition method implemented in HYPERCHEM 7.51 software [32]. Steric and structural parameters were obtained from DRAGON 6 software.

The capability of the QSAR models to predict correctly the BR values of an external series (not used as training set) was measured through the external coefficient of determination ($R^2$) and the cross-validation coefficient ($q^2$). Here determined by leave-one-out (LOO) cross-validation. The possibility that the correlation found between the selected MDs and each dependent variable were just due to statistical chance was ruled out using $Y$-scrambling [33] (thirty iterations were performed). Commonly, models with $R^2 > 0.75$ and $q^2 > 0.5$ are required [34]. The ability of one of the QSAR models to predict correctly the BR values of an external series (not used as training set) was measured through the external coefficient of determination ($0 < R^2_{\text{ext}} < 1$).

### Inhibitor candidates

The sources of the 24 flavodoxin inhibitors selected here for the QSAR analysis, their purities, and the chemical characterizations of those made to order by Maybridge or synthesized at home, are reported in detail in Galano et al. [20].

### Biological activity assays

Table 1 shows the results of the biological responses determined per compound in Galano et al. [20]. The biological assays performed for determining such biological activities are also detailed there.

Table 2: Statistical parameters, value ranges and description of the MDs and BRs analyzed.
Results

QSAR study for variants of inhibitors I and II

The observed improvement in the therapeutic index (TI) exhibited by some of the derivatives purposely designed in [20] prompted us to apply a classical QSAR approach to facilitate further optimizations. Twenty four structurally congeneric compounds, including I, II (Table 1) constituted the starting point. The values of the molecular descriptors finally selected for the QSAR models are summarized in Table S1.

Hierarchical CA revealed several clusters (Figure S1) evidencing a molecular diversity, which is also reflected in the value ranges of both MDs and BRs shown in Table 2.

**QSAR model for LogKd:** This BR passed the normality test: the histogram in Figure 2 displays the typical Gauss bell curve of a Normal probability distribution, and the BR values fitted a straight line in the Normal probability plot (Figure 2). Typified kurtosis and asymmetry parameters also demonstrated compliance with normality (not shown). Six outliers (compounds 6, 35, 38, 40 and 45) were detected using

![Figure 2: Histograms (1) and normality test plots (2) for each BR analyzed: a) LogKd; b) Log(1/MIC); c) Log(1/MCC); d) LogTI.](image)
standard statistical tests (residuals, standardized residuals, studentized residuals and Cook distances) and were removed. The training set, defined by CA comprised 15 compounds II, 1-3, 5, 7, 31-33, 36, 37, 39, 41, 42 and 44. The remainder compounds: 1, 4, 34 and 43 constituted the test set.

The best model found for log\(K_d\) was:

\[
\log K_d = 0.02(\pm 0.01)\%X + 0.29(\pm 0.12)TE + 1.04(\pm 0.5)\eta - 2.77(\pm 2.08) (1)
\]

\([s=0.167; F=25.41; SPRESS=0.237]\)

The model combines three MDs: %X, TE and \(\eta\), which exhibit low pair correlations (0.265 for %X and TE; 0.359 for %X and \(\eta\) and 0.002 for TE and \(\eta\)). The \(R^2\) (0.874) indicates that there is a good correlation between the observed values and the MDs selected. On the other hand, \(q^2\) (0.747) and \(R^2_{\text{ext}}\) (0.924) values are indicative of good internal and external predictability of this model. Besides, \(Y\)-scrambling suggests there is neither chance correction nor chance prediction in the model (Figure S2). The observed \(K_d\) values determined by ITC and the predicted values are compared in Table 3. Compound 1 is predicted as the most affine one in this series whereas compound 37 is predicted as the least affine one, which fully coincides with the experimental results.

**QSAR model for Log(1/MIC):** This BR did not initially met the normality requirement (Figure 2c and 2d), which was confirmed by both typified kurtosis and asymmetry values (not shown). Normality was obtained by removing compounds 7, 36 and 39. After this, compounds 37 and 40-42 and I were eliminated as outliers. Because as many as 8 compounds had to be discarded, we preferred to use the remaining 16 compounds as training set. Thus, no test set was extracted for external validation. The training set, constituted by compounds: II, 1-6, 31-35, 38 and 43-45 lead to the following model:

\[
\log(1/MIC) = -0.25(\pm 0.08)nCb- -8.48(\pm 3.19)Hy + 1.38(\pm 0.61)\omega - 10.5(\pm 4.21) (2)
\]

\([s=0.156; F=16.175; SPRESS=0.198]\)

The model combines three MDs: nCb-, Hy and \(\omega\), exhibiting low pair correlations (0.074 for nCb- and Hy; 0.004 for nCb- and \(\omega\); and 0.22 for Hy and \(\omega\)). A high correlation was also obtained (\(R^2=0.801\)), the \(q^2\) (0.682) value warrants a good internal predictability and the \(Y\)-scrambling analysis discards both chance correlation and chance prediction (Figure S2). The observed Log(1/MIC) values and the predicted ones are compared in Table 4. The most potent compounds against \(H. pylori\): 43 and 44 were correctly predicted by the model, whereas the least potent one: 33 was predicted as the second least potent one.

**QSAR model for Log(1/MCC):** Compound 33 was removed to ensure the normality condition (Figure 2c and 2f). Then, compounds 5, 34 and 45 were removed as outliers. Compounds: I, II, 2-4, 6, 31, 32, 36-41, 43 and 44 were the training set, and compounds 1, 7, 35 and 42 were chosen as test set. The orthogonality between the selected MDs was checked and all pair wise correlations were \(<0.3\) (not shown). The developed QSAR model is shown in equation 3:

\[
\log(1/MCC) = -0.33(\pm 0.07)nCb- -3.71(\pm 0.70)Hy - 0.31(\pm 1.11)TE - 3.07(\pm 0.62) (3)
\]

\([s=0.302; F=11.583; SPRESS=0.409]\)

\(R^2\) (0.743) and \(q^2\) (0.53) values are lower than in the previous QSAR models and \(R^2_{\text{ext}}\) (0.512) is quite low, indicating poorer correlation and external predictability for this model.

### Table 3: Observed and predicted \(\log K_d\) values.

| Compound | Y Obs. | Y Pred. | Residual |
|----------|--------|---------|----------|
| 1*       | -0.37  | -0.32   | -0.05    |
| 2        | 0.18   | 0.23    | -0.05    |
| 3        | 0.22   | 0.27    | -0.05    |
| 5        | 0.28   | 0.22    | 0.06     |
| 7        | 0.26   | 0.15    | 0.11     |
| II       | 0.54   | 0.77    | -0.23    |
| 31       | 0.90   | 0.85    | 0.05     |
| 32       | 0.74   | 0.67    | 0.06     |
| 33       | 1.00   | 0.79    | 0.21     |
| 36       | 0.57   | 0.67    | -0.10    |
| 37a      | 1.20   | 1.05    | 0.15     |
| 39       | 1.04   | 0.78    | 0.26     |
| 41       | 0.65   | 0.88    | -0.23    |
| 42       | 0.87   | 0.91    | -0.04    |
| 44       | 0.82   | 0.98    | -0.16    |

*Predicted as the highest affinity compound

**Table 4: Observed and predicted Log(1/MIC) values.**

| Compound | Y Obs. | Y Pred. | Residual |
|----------|--------|---------|----------|
| 1        | -0.38  | -0.43   | 0.05     |
| 2        | -0.38  | -0.30   | -0.08    |
| 3        | -0.38  | -0.31   | -0.07    |
| 4        | -0.08  | -0.07   | -0.01    |
| 5        | -0.88  | -0.96   | 0.08     |
| 6        | -0.30  | -0.52   | 0.22     |
| II       | -0.38  | -0.37   | -0.01    |
| 31       | -0.68  | -0.49   | 0.19     |
| 32       | -0.38  | -0.23   | -0.15    |
| 33       | -0.90  | -0.95   | 0.05     |
| 34       | -0.38  | -0.28   | -0.10    |
| 35       | -0.38  | -0.47   | 0.09     |
| 38       | -0.68  | -0.45   | -0.24    |
| 43a      | 0.28   | -0.01   | 0.29     |
| 44a      | -0.03  | -0.01   | -0.02    |
| 45       | -0.03  | -0.12   | 0.09     |

*Predicted as the highest inhibitory activity compound

*Predicted as the lowest inhibitory activity compound

**Discussion**

**QSAR models for affinity and inhibitory properties of [(E)-2-R-vinyl]benzene derivatives**

QSAR studies are based on the assumption that similar molecules have similar activities, and summarize existing relationships between chemical structures and biological activity within a dataset of structurally similar chemicals. Therefore, QSARs allow to predict the activities of new compounds using regression models relating a set of predictor variables to a biological response variable. Predictors may be physico-chemical properties or theoretical or structural parameters of compounds, while the response variables generally consist of biological activities such as binding affinity, potency, etc. We have performed classic QSAR analysis on compounds I and II, and analogues thereof, all sharing a [(E)-2-R-vinyl]benzene substructure. Several outliers were identified and excluded from the database. Reported sources for outliers in QSAR studies include flexible binding sites, inappropriate...
calculation of selected MDs, different binding modes, etc. [35,36]. The specific reasons why those compounds are outliers are at present not known.

Four different BRs were modeled. For two of them, we found either no model with good statistical parameters (Q SAR model for Log(TI)) or a model that showed a poor correlation and poor external predictability (Q SAR model for Log(1/MIC)). In contrast, the Q SAR models for LogK_{H-p} and for Log(1/MIC) appear promising. As shown in eq. 1, the developed model for LogK_{H-p} describes the affinity of ligands for Hp-Fld by means of electronic and constitutional terms. Equation 1 suggests that decreasing %X (percentage of halogen atoms) decreases LogK_{H-p}, thus increasing the affinity of the compounds for Hp-Fld. It should be noticed that although this term is statistically significant, its contribution to the value of the BR is small. Similarly, decreasing TE (total energy) or \eta (chemical hardness) lowers the value of LogK_{H-p}, thus increasing the affinity of the complex. The TE is related to the amount and type of bonds present in a given compound. In our context, its contribution to affinity suggests that reducing the number of heteroatoms and/or shifting from fluorine to iodine along the halogen series would increase the affinities of the compounds. On the other hand, \eta, whose contribution to LogK_{H-p} is greater than that of TE, is inversely related to the reactivity of compounds. According to eq. 1, the lower the \eta value (e.g. higher the reactivity) the lower the LogK_{H-p} value and hence higher the compound/Hp-Fld affinity. The model correctly identifies the more and less affine compounds and its external predictability is high.

The Q SAR model developed for Log(1/MIC) is given in eq. 2. The model suggests that decreasing nCh- (number of substituted benzene carbon) will increase the inhibitory activity. This is in perfect agreement with the above conclusion drawn from LogK_{H-p} model which states that decreasing the number of bonds (benzene Carbon substitutions in this case) could increase the affinity of the compounds and consequently its inhibitory potency. Besides, it also could reflect on steric issues related to binding to flavodoxin. Meanwhile, the term H_{Hy} (hydrophilic factor) has also a negative contribution to this BR, which indicates that more hydrophobic substituents contribute to a greater inhibitory effect. Finally, more electrophilic compounds (greater electrophilicity index: \omega) also contribute to a greater inhibitory effect, which might indicate that the Hp-Fld binding site is an electron-rich site.

Conclusions

Two Q SAR models for target affinity and inhibitory activities of [(E)-2-R-vinyl]benzene derivatives have been developed that show high statistical correlation and predictive capacity. They provide insights about the type of physical-chemical interaction of these inhibitors with their possible biological receptor (the flavodoxin protein) as well as simple structural information about how to optimize such compounds in order to guide the design of variants with improved affinity and improved inhibitory effect towards Hp cells. The discovery of novel chemicals with such specific antimicrobial properties against Hp is urgently needed at present for the treatment of the diseases associated with these bacteria.

Acknowledgement

Galano, J.J. is a recipient of a Ph. D. studies fellowship awarded by Banco Santander and University of Zaragoza (Spain). This work was supported by grants BFU2010-16297 and BFU2010-19451 (Ministerio de Ciencia e Innovación: MICINN, Spain) and Grupo Protein Targets B09 (Diputación General de Aragón, Spain).

References

1. Hansch C, Fujita T (1964) p-o-n: Analysis. A Method for the Correlation of Biological Activity and Chemical Structure. J Am Chem Soc 86: 1616-1626.
2. free sm jr, wilson jw (1964) A mathematical contribution to structure-activity studies. J Med Chem 7: 395-399.
3. Ban T, Fujita T (1969) Mathematical approach to structure–activity study of sympathomimetic amines. Norepinephrine-uptake inhibition. J Med Chem 12: 353-356.
4. Kubinyi H (1976) Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson Analysis. J Med Chem 19: 587-600.
5. Kubinyi H (1976) Quantitative structure-activity relationships. IV. Non-linear dependence of biological activity on hydrophobic character: a new model. Arzneimittelforshung 26: 1991-1997.
6. Kubinyi H (1977) Quantitative structure–activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J Med Chem 20: 625-629.
7. Kubinyi H (1977) Quantitative structure-activity relationships. V. A simple simple approach for Fujita-Ban and Free-Wilson analyses. Arzneimittelforshung 27: 750-758.
8. Kubinyi H, Kehrnhahn OH (1976) Quantitative structure-activity relationships. 3.1 A comparison of different Free-Wilson models. J Med Chem 19: 1040-1049.
9. Kubinyi H, Kehrnhahn OH (1976) Quantitative structure-activity relationships. 1. The modified Free-Wilson approach. J Med Chem 19: 578-586.
10. Kubinyi H, Kehrnhahn OH (1978) Quantitative structure-activity relationships. VI. Non-linear dependence of biological activity on hydrophobic character: calculation procedures for bilinear model. Arzneimittelforshung 28: 598-601.
11. Topliss JG (1972) Utilization of operational schemes for analog synthesis in drug design. J Med Chem 15: 1006-1011.
12. Bruce MG, Maaroos HI (2008) Epidemiology of Helicobacter pylori infection. Helicobacter 13 Suppl 1: 1-6.
13. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315.
14. Everhart JE (2000) Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 29: 559-578.
15. Malfertheiner P, Megraud F, O'Morain C, Bell D, Bianchi Porro G, et al. (1997) Current European concepts in the management of Helicobacter pylori infection—-the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 9: 1-2.
16. Chalker AF, Minehart HW, Hughes NJ, Koretk KK, Lometto MA, et al. (2001) Systematic identification of selective essential genes in Helicobacter pylori by genome prioritization and allelic replacement mutagenesis. J Bacteriol 183: 1259-1268.
17. Cresmades N, Bueno M, Toja M, Sancho J (2005) Towards a new therapeutic target: Helicobacter pylori flavodoxin. Biophys Chem 115: 267-276.
18. Freigang J, Diederichs K, Schäfer KP, Welte W, Paul R (2002) Crystal structure of oxidized flavodoxin, an essential protein in Helicobacter pylori. Protein Sci 11: 253-261.
19. Cresmades N, Velázquez-Campoy A, Martínez-Júlvez M, Neira JL, Pérez-Dorado I, et al. (2008) Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. ACS Chem Biol 4: 928-938.
20. Galano JJ, Alías M, Pérez R, Velázquez-Campoy A, Hoffman PS, et al. (2013) Improved flavodoxin inhibitors with potential therapeutic effects against Helicobacter pylori infection. J Med Chem 56: 6248-6258.
21. Everitt BS (1993) Cluster Analysis. London: Edward Arnold.
22. Polhemus N (2000) Statgraphics Plus v.5.1, Statistical Graphics Corporation. p. Statistical Package.
23. Todeschini R, Consonni V (2000) Handbook of Molecular Descriptors. Weinheim, Germany: Wiley-VCH.
24. Tatele sr, DRAGON v.6.0 p. (2010) Software for Molecular Descriptor Calculation.
25. Ghose AK, Crippen GM (1987) Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships I. Partition Coefficients as a measure of hydrophobicity. J Comput Chem 7: 565-577.

26. Ghose AK, Pritchett A, and Crippen GM (1988) Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships 3. Modeling hydrophobic interactions. J Comput Chem 9: 80-90.

27. Stewart JJP (1989) Optimization of parameters for Semiempirical Methods I. Method. J Comput Chem 10: 209-221.

28. Dewar MJ, Zoebisch EG, Healy EF, Stewart JP (1985) Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 107: 3902-3909.

29. Parr RG, László VS, Shubin L (1999) Electrophilicity Index. J Am Chem Soc 121: 1922-1924.

30. Parr RG and Pearson RG (1983) Absolute hardness: comparison parameter to absolute electronegativity. J Am Chem Soc 105: 7512-7516.

31. Miller KJ (1990) Additivity Methods in Molecular Polarizability. J Am Chem Soc 112: 8533-8542.

32. Hyperchem v.7.51. (2002) Hypercube Inc.: Gainesville, FL (USA). Molecular Modeling Program.

33. Dogra SK "Y Scrambling" From QSARWorld-A Strand Life Sciences Web Resource. Oct 06, (2011)

34. Tropsha A, Gramatica P and Gombar VK (2003) The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSAR Models. Qsar & Combinatorial Science 22: 69-77.

35. Kim KH (2007) Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers? J Comput Aided Mol Des 21: 421-435.

36. Kim KH (2007) Outliers in SAR and QSAR: is unusual binding mode a possible source of outliers? J Comput Aided Mol Des 21: 63-86.